Protia Inc

Protia Inc maintains a strong liquidity position with a current ratio of 10.83 and a low debt-to-equity ratio of 0.01, indicating minimal leverage and strong balance sheet health. The company's liquidity_fpt of 2964984840 KRW in cash and equivalents supports operational flexibility and financial resilience. The price-to-book ratio of 2.01 and price-to-tangible-book ratio of 2.01 suggest a moderate premium to book value, consistent with its asset-light business model. Profitability metrics show a return on equity of 14.57% and return on assets of 13.54%, both exceeding the typical thresholds for the medical equipment and supplies industry. These returns reflect efficient asset utilization and strong earnings generation relative to equity and total assets. Gross profit of 9303733400 KRW and operating income of 3579843680 KRW support a healthy margin structure, with net income of 4471384230 KRW translating to a price-to-earnings ratio of 13.82, which is in line with industry norms. The company's revenue is concentrated in its core diagnostic reagents and equipment business, with no disclosed geographic diversification beyond its Korean base. This concentration may expose the company to regional economic and regulatory risks, though the domestic healthcare market remains stable. No material revenue concentration risks are currently flagged in the data. Growth trajectory is supported by a strong free cash flow of 3811164370 KRW and capital expenditure of -1124961860 KRW, indicating disciplined reinvestment and cash generation. The outlook for the current fiscal year shows a positive revenue trend, with no immediate dilution or liquidity pressures identified. Analyst estimates align with the company's reported revenue and EPS, suggesting stable performance expectations. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt levels and strong cash position reduce financial distress risk. No dilution sources were identified in the data, and the dilution potential remains low. The absence of recent equity issuance or ATM/shelf disclosures supports this assessment. Recent events include the company's continued focus on R&D in diagnostic reagents and point-of-care testing, with no material regulatory or litigation events disclosed in the latest filings. The company's operating cash flow of 3004132510 KRW supports ongoing operations and reinvestment.